ABOUT THE EVENT
Date: Wednesday, November 12, 2025 10–11am CST
Event Location: Virtual
X-ray crystallography is a useful and informative screening technique for fragment-based drug discovery (FBDD). It is employed most effectively as a primary screen to detect the binding of fragment hits to protein target sites, while simultaneously elucidating binding poise and identifying possibilities for fragment development. The high information content of X-ray crystallography gives a powerful platform for structure-based drug discovery, and therefore, dedicated X-ray crystallography screening facilities have been established at several synchrotrons, for example, PSI’s Fast Fragment and Compound Screening (FFCS) pipeline at the Swiss Light Source. Such facilities have streamlined research by providing both expertise and dedicated equipment to academic and industrial users. In this presentation, Dr. May Sharpe will introduce FFCS pipeline and discuss the initial results of a screening campaign that was carried out in collaboration with Chemspace using their recently developed REAL Crystallographic fragment library. This crystallographic data for this campaign was the first to be acquired at our newly upgraded SLS2.0 PXIII beamline.
